An observational study in Mucormycosis, sponsored by University Hospital, Grenoble. Completed at 21 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-08.
Sponsored by University Hospital, Grenoble · Observational
Mucormycosis is an invasive fungal infection affecting patients with various clinical conditions especially patients with heavy immunosuppression or patients with trauma or extensive burns.
ZygoRéa is a retrospective and multicentric French study aimed to evaluate survival of patients with mucormycosis admitted in ICU at day-28 after admission. This study will also try also to describe the epidemiology of patients admitted in ICU.
Mucormycosis is an invasive fungal infection affecting patients with various clinical conditions especially patients with heavy immunosuppression or patients with trauma or extensive burns. The incidence of Mucormycosis is currently increasing reaching 7% of invasive fungal infections in some immunocompromised patients. Because of its aggressive nature, Mucormycosis is associated with poor survival and high morbidity ; mortality is estimated between 16% and 64% according to different retrospective studies. No study has ever evaluated prognosis of patients with mucormycosis admitted in intensive care units (ICU).
ZygoRéa is a retrospective and multicentric French study aimed to evaluate survival of patients with mucormycosis admitted in ICU at day-28 after admission. This study will also try also to describe the epidemiology of patients admitted in ICU and to evaluate the prognosis of different subgroups of patients according to :
Twenty-one French ICU are currently including more than 45 patients.
patients with mycormycosis hospitalized in intensive care unit during the 2008-2016 period
Exclusion Criteria:
Mortality at Day 28
Mortality at Day 28 after ICU admission
Time frame: up to 28 days
Mortality at Day 90
Mortality at Day 90 after ICU admission
Time frame: up to 90 days
Mortality during the ICU stage
Mortality status (alive or dead) at the end of the ICU stage
Time frame: up to 28 days
Length stay in ICU
number of days in intensive care Unit
Time frame: up to 28 days
Length stay of hospitalization
number of days in hospital
Time frame: up to 90 days
Mortality during the hospitalization
Mortality status (alive or dead) at the end of the hospitalization
Time frame: up to 90 days
Prognostic criteria
Prognostic factors of mortality in intensive care units
Time frame: up to 28 days
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Grenoble